Chilton, United Kingdom

Norman Barras

This inventor holds 4 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Norgine Bv, Norgine Europe Bv. Active years: 2007-2013.

USPTO Granted Patents = 4 

% Patents Active = 50.0


 

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 68(Granted Patents)


Location History:

  • Chilton, GB (2007 - 2010)
  • Mid Glamorgan, GB (2013)

Company Filing History:


Years Active: 2007-2013

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Norman Barras

Introduction

Norman Barras is a notable inventor based in Chilton, GB, recognized for his contributions to medical treatments. He holds a total of four patents, showcasing his innovative approach to addressing various health conditions.

Latest Patents

One of his latest patents involves the treatment of faecal incontinence and other conditions using 1R, 2S-methoxamine. This compound can be applied topically for effective treatment at low doses, without causing local or systemic side effects, such as affecting blood pressure. Additionally, 1R, 2S-methoxamine has potential applications in treating other gastrointestinal disturbances, serving as a pressor agent, a nasal decongestant, and in ophthalmology, all while maintaining a low risk of significant side effects.

Career Highlights

Throughout his career, Norman Barras has worked with reputable companies, including Norgine BV and Norgine Europe BV. His work in these organizations has contributed to the development of innovative medical solutions.

Collaborations

Some of his notable coworkers include Ian David Cox and Jeffrey Martin Thompson, who have collaborated with him on various projects.

Conclusion

Norman Barras's work exemplifies the spirit of innovation in the medical field, particularly through his patents that address critical health issues. His contributions continue to impact the treatment landscape positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…